Weight loss, however, is a secondary benefit: participants in these trials lost roughly 24 kg over 812 weeks, making berberine primarily a metabolic health supplement rather than a weight loss drug
The Optimization CentreTM in Boca Raton is where you can get information about the life-changing improvements of plastic surgery and aesthetic treatments
Weight Loss Plateaus Are Normal and Seen in Every Major GLP-1/GIP Study The Standard Weight-Loss Curve Clinical trials consistently show that weight loss with GLP-1 and GLP-1/GIP medications follows a predictable pattern: Rapid weight loss early Gradual slowing over time A plateau phase where weight stabilizes This pattern has been observed across: Semaglutide trials ( STEP program ) Tirzepatide trials ( SURMOUNT-1 , SURMOUNT-4 ) Long-term cardiovascular outcomes studies ( SELECT ) In these studies, most participants lost weight more rapidly during the first several months, then experienced a gradual slowing and reached their average maximum weight loss around 918 months , after which weight tended to stabilize rather than continue to drop indefinitely
Regular check-ins with a healthcare provider are crucial for adjusting medication, addressing side effects, and ensuring the overall health plan is effective and safe while using semaglutide
Compared to other medications, tirzepatide has shown superior efficacy in promoting weight reduction
